News

The research assistant professor, pathology and laboratory medicine, University of Pennsylvania, talked about the ongoing research in her lab on understanding the mechanisms and consequences of TDP-43 aggregation in Alzheimer Disease. [WATCH TIME: 4 minutes]

Although popular at the turn of the century, the use of platform injectable therapies has subsided significantly with the introduction of oral agents, with became the most frequently initiated therapies by 2020.

Several patients have completed the 18-month trial and have moved on to the open-label extension, where they will be followed for an additional 12 months.

The associate professor of neurochemistry at the University of Gothenburg in Sweden talked about a pilot study that explored the potential of finger prick tests to remotely collect blood and provide reliable biomarker results for Alzheimer disease diagnosis. [WATCH TIME: 5 minutes]

With other potential antiamyloid therapies on the way, the proposal would allow for additional coverage of PET scans to check for amyloid-ß, potentially reducing provider and patient burden.

The director of research for internal medicine and geriatrics at Indiana University School of Medicine provided perspective on ways to effectively streamline cognitive screening in timely and accurate manor. [WATCH TIME: 4 minutes]

The 52-week, dose-ascending trial will have data read out in the first half of 2024, with long-term safety and efficacy evaluated over a 5-year period following completion of the initial trial.

In total, 33% of the study participants died within 180 days after initiating their first opioid prescription, compared with 6.4% of those unexposed.

In an analysis of more than 2700 patients aged 55 years or older on semaglutide, the therapy demonstrated a safety profile that was similar to that observed in the overall population.

The neurologist in the Danish Dementia Research Center at Rigshospitalet in Copenhagen, Denmark, discussed a cohort study that examined the association between opioid use and the risk of mortality in an older patient population living with dementia. [WATCH TIME: 5 minutes]

Change in phosphorylated tau231, the primary outcome, favored nicotinamide despite not reaching statistical significance.

With the recent approval of lecanemab (Leqembi; Eisai), NeurologyLive took a closer look at the Alzheimer pipeline, and the potential agents clinicians should keep an eye on in the coming years.

Using a cohort of more than 600 cognitively normal adults, the MIND diet failed to outperform a control diet of mild caloric restriction on several outcomes, including cognition and hippocampal volumes.

The professor in the department of internal medicine at RUSH Medical College talked about estimating the prevalence of Alzheimer disease to uncover the variability in disease prevalence at a micro-level and its implications for public health programs. [WATCH TIME: 5 minutes]

The associate professor of neurology at the Indiana University School of Medicine provided commentary on a study comparing traditional cognitive screening methods and the Linus Health Digital Clock and Recall test.

David Bates, PhD, chief executive officer and co-founder of Linus Health, provided insight on the transition of lecanemab to traditional approval, and how this decision impacts future care for Alzheimer disease.

In a cohort of nearly 800 frail adults and elderly patients with neuropsychiatric symptoms, pimavanserin showed similar rates of treatment-related adverse events and discontinuations because of TEAEs to placebo.

The clinical relevance of donanemab was demonstrated through a slowing of clinical decline, stability of clinical symptoms, lowered risk of advancement to next clinical stage, and lower risk of meaningful within-patient change.

The associate professor of neurology at the Indiana University School of Medicine provided insight on the distinguishable characteristics of certain cognitive screening tools and the advantages to each. [WATCH TIME: 3 minutes]

Tenecteplase, a genetically modified molecule of alteplase, had similar benefit and safety as alteplase, and was not modified by baseline occlusion site.

The director of research for internal medicine and geriatrics at Indiana University School of Medicine provided perspective on navigating challenges with newly approved treatments for Alzheimer disease, and using resources efficiently. [WATCH TIME: 5 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

A comparison between impaired scores on Digital Clock and Recall and impaired scores on Montreal Cognitive Assessment produced a 76% concordance.

According to diary data, caregiver's perceived reciprocity showed a substantial direct influence on the occurrence of behavioral symptoms on both the current day and the subsequent day for patients with Alzheimer disease and related dementias.

The postdoctoral fellow at the University of California San Diego discussed using CRISPR-based gene editing to alter the amyloid precursor protein gene in mice models with symptoms of Alzheimer disease. [WATCH TIME: 5 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the Alzheimer's Association.

After 4 years of treatment, more than 95% of infants on risdiplam maintained the ability to swallow, an aspect of everyday life that is commonly lost within 2 years in patients with SMA.

Neurology News Network for the week ending July 15, 2023. [WATCH TIME: 3 minutes]